GSK plc
linerixibat
cholestatic pruritus in primary biliary cholangitis (PBC)
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on linerixibat for cholestatic pruritus in primary biliary cholangitis (PBC) is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“the FDA has set a PDUFA action date of March 27, 2026”